Arne Östman's Group

Denna sida på svenska

Our research aims at an improved understanding of autocrine and paracrine growth factor signaling in cancer. Within this context we perform studies in cell biology, tumor biology, pathology and experimental cancer therapy.

The studies in cell biology analyze how growth factor signaling is controlled by protein tyrosine phosphatases (PTPs). This class of enzyme has recently been shown to be regulated by reactive oxygen species, suggesting that they act as intermediates in a previously un-recognized crosstalk between redox-signaling and growth factor signaling.

The cancer-related studies deal with the inter-play between malignant and non-malignant cells in solid tumors. In this context, we are particularly interested in the cancer-associated fibroblasts (CAFs) which are major constituents of the tumor micro-environment. Recent studies in our group have identified CAF-derived proteins which impact on cancer growth, metastasis, prognosis and response to treatment.

We have an active interest in combining pre-clinical studies with involvement in drug-development and clinical studies. A number of our projects are performed together with partner groups in different KI-based cancer research networks, e.g, STARGET and BRECT, and involve the participation of experts in oncology and pathology.


Some of our projects also involve collaborations with commercial partners.

Group members

Arne Östman, Professor, Group Leader
Carina Strell, PhD, Postdoc
Monika Ehnman, PhD, Postdoc
Mercedes Herrera Torres, PhD, Postdoc
Sara Corvigno, MD, PhD student
Artur Mezheyeuski, MD, PhD student
Elin Sjöberg, PhD student
Magnus Frödin, MD, PhD student
Alessandro Mega, PhD student
Per Sandström, MD, PhD
Hanna Dahlstrand, MD, PhD

Selected publications between 2009-2014

CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth.
Augsten M, Hägglöf C, Olsson E, Stolz C, Tsagozis P, Levchenko T, et al
Proc. Natl. Acad. Sci. U.S.A. 2009 Mar;106(9):3414-9

Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer.
Paulsson J, Sjöblom T, Micke P, Pontén F, Landberg G, Heldin C, et al
Am. J. Pathol. 2009 Jul;175(1):334-41

Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer.
Saito R, Micke P, Paulsson J, Augsten M, Peña C, Jönsson P, et al
Cancer Res. 2010 Apr;70(7):2644-54

12/15-lipoxygenase-derived lipid peroxides control receptor tyrosine kinase signaling through oxidation of protein tyrosine phosphatases.
Conrad M, Sandin A, Förster H, Seiler A, Frijhoff J, Dagnell M, et al
Proc. Natl. Acad. Sci. U.S.A. 2010 Sep;107(36):15774-9

Global proteomic assessment of the classical protein-tyrosine phosphatome and "Redoxome".
Karisch R, Fernandez M, Taylor P, Virtanen C, St-Germain J, Jin L, et al
Cell 2011 Sep;146(5):826-40

Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling.
Frings O, Augsten M, Tobin N, Carlson J, Paulsson J, Pena C, et al
Am. J. Pathol. 2013 Jun;182(6):2037-47

STC1 expression by cancer-associated fibroblasts drives metastasis of colorectal cancer.
Peña C, Céspedes M, Lindh M, Kiflemariam S, Mezheyeuski A, Edqvist P, et al
Cancer Res. 2013 Feb;73(4):1287-97

Selective activation of oxidized PTP1B by the thioredoxin system modulates PDGF-β receptor tyrosine kinase signaling.
Dagnell M, Frijhoff J, Pader I, Augsten M, Boivin B, Xu J, et al
Proc. Natl. Acad. Sci. U.S.A. 2013 Aug;110(33):13398-403

Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15.
Bruzzese F, Hägglöf C, Leone A, Sjöberg E, Roca M, Kiflemariam S, et al
Cancer Res. 2014 Jul;74(13):3408-17

Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties.
Augsten M, Sjöberg E, Frings O, Vorrink S, Frijhoff J, Olsson E, et al
Cancer Res. 2014 Jun;74(11):2999-3010

Review articles and commentaries

Cancer-associated fibroblasts and tumor growth--bystanders turning into key players.
Ostman A, Augsten M
Curr. Opin. Genet. Dev. 2009 Feb;19(1):67-73

The tumor microenvironment controls drug sensitivity.
Ostman A
Nat. Med. 2012 Sep;18(9):1332-4

Full list of publications